BioGeometry and GeneVax Collaborate to Enhance Vaccine Design with Advanced Protein AI Models

Recently, BioGeometry, a leader in digital biology, and GeneVax, an innovative vaccine company, announced a strategic partnership. They will jointly develop new vaccines and antibody products for blood, respiratory, and vector-borne diseases, and establish an AI-powered vaccine design platform to accelerate intelligent vaccine development in China.

Vaccines are crucial for disease prevention and control, but traditional development methods are slow, expensive, and risky. With advancements in geometric deep learning and generative AI, artificial intelligence is playing a growing role in creating innovative vaccines, especially in protein design and optimization. Proper use of AI can speed up vaccine development, increase success rates, and make previously impossible designs a reality, pushing forward the mission of advancing public health through intelligent vaccination.

BioGeometry is dedicated to building a generative AI protein design platform for the biopharmaceutical and biomanufacturing industries. In 2021, their team pioneered the use of diffusion generative models for 3D molecular structure generation, with a key paper being one of the top 50 most cited in AI in 2022.

In June, BioGeometry launched GeoFlow, a generative AI protein design model. By integrating sequence and structural data with geometric deep learning and flow matching generative models, GeoFlow achieved AlphaFold3-level performance in antigen-antibody complex prediction. GeoFlow is now part of BioGeometry’s GeoBiologics platform, aiding in antibody design, enzyme discovery, and antigen modification, helping clients quickly and accurately find target molecules.

GeneVax specializes in innovative vaccine development and has built six major technology platforms, including intelligent antigen design, rapid reassortment for reverse genetics, recombinant nanoparticles, RNA vaccines, vaccine adjuvants, and needle-free injection technologies. Their team has extensive experience in vaccine development, production, and clinical research.

This strategic partnership will leverage the strengths of both companies to advance innovative vaccine development and production, creating cutting-edge vaccines in China and contributing to global health.